3806 related articles for article (PubMed ID: 32788194)
21. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity.
Sakaguchi W; Kubota N; Shimizu T; Saruta J; Fuchida S; Kawata A; Yamamoto Y; Sugimoto M; Yakeishi M; Tsukinoki K
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825469
[TBL] [Abstract][Full Text] [Related]
22. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
[TBL] [Abstract][Full Text] [Related]
23. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
24. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
25. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
[TBL] [Abstract][Full Text] [Related]
26. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
[TBL] [Abstract][Full Text] [Related]
27. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
28. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
Chen HY; Huang C; Tian L; Huang X; Zhang C; Llewellyn GN; Rogers GL; Andresen K; O'Gorman MRG; Chen YW; Cannon PM
J Virol; 2021 Oct; 95(22):e0096621. PubMed ID: 34495700
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
[TBL] [Abstract][Full Text] [Related]
32. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
33. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
Cantuti-Castelvetri L; Ojha R; Pedro LD; Djannatian M; Franz J; Kuivanen S; van der Meer F; Kallio K; Kaya T; Anastasina M; Smura T; Levanov L; Szirovicza L; Tobi A; Kallio-Kokko H; Österlund P; Joensuu M; Meunier FA; Butcher SJ; Winkler MS; Mollenhauer B; Helenius A; Gokce O; Teesalu T; Hepojoki J; Vapalahti O; Stadelmann C; Balistreri G; Simons M
Science; 2020 Nov; 370(6518):856-860. PubMed ID: 33082293
[TBL] [Abstract][Full Text] [Related]
34. Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?
Pique-Regi R; Romero R; Tarca AL; Luca F; Xu Y; Alazizi A; Leng Y; Hsu CD; Gomez-Lopez N
Elife; 2020 Jul; 9():. PubMed ID: 32662421
[TBL] [Abstract][Full Text] [Related]
35. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
37. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
38. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
[TBL] [Abstract][Full Text] [Related]
39. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
[TBL] [Abstract][Full Text] [Related]
40. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Case JB; Rothlauf PW; Chen RE; Kafai NM; Fox JM; Smith BK; Shrihari S; McCune BT; Harvey IB; Keeler SP; Bloyet LM; Zhao H; Ma M; Adams LJ; Winkler ES; Holtzman MJ; Fremont DH; Whelan SPJ; Diamond MS
Cell Host Microbe; 2020 Sep; 28(3):465-474.e4. PubMed ID: 32798445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]